The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332

Last update: 31/07/2024

There are currently 37 open trials. In 141 locations

What is a Clinical Trial?

Find out more information
Step 2: Choose a Trial

There are currently 37 open trials

Step 3: View Details
i View Full Trial Details

Trial Title:

Teclistamab monotherapy for relapsed and/or refractory myeloma (MajesTEC-10)

Treatments:

Teclistamab

Myeloma stage:

Relapsed, Refractory

Trial phase:

I

Summary

Summary:

This trial is comparing investigating the safety and effectiveness of two versions of the bispecific antibody drug, teclistamab (Tecvayli®) when used as monotherapy (on its own), for the treatment of relapsed and/or refractory myeloma patients.

Locations

Locations:

Hammersmith Hospital, London;
Derriford Hospital, Plymouth

Who can enter the study?

Who can enter the study?:

Relapsed and/or refractory myeloma patients who:

  • Have received one to three previous lines of treatment including a proteosome inhibitor such as bortezomib (Velcade ®), a CD38 monoclonal antibody such as daratumumab (Darzalex®), and lenalidomide (Revlimid®).
What's involved?

What's involved?:

Patients will be randomised to receive one of two variations of subcutaneous (under the skin) teclistamab monotherapy (on its own).

Patients will receive treatment until there are signs of disease progression or the treatment is discontinued for other reasons.

Patients will be required to attend outpatient clinics for regular check-ups and blood tests.

Patients will be followed up for up to 3 years.

Clinical Information

Clinical Information
(for Medical Professionals):

A Phase I Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma. The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).

For more information, click here.

Find

Find out more about Myeloma UK:

Visit www.myeloma.org.uk

Do you want to talk to someone? Call our myeloma Infoline
0800 980 3332